Develop, qualify immunological assays, and provide clinical sample testing for AAV-based gene therapy clinical candidates
Active Awarded Last action
- Contract number
- 75N91025F00024
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,557,516
Award facts
- Contract value 100% obligated
- $4,557,516.00 Current and potential, with all options
- Completion date 22% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $2,047,008 | |
| Original award | $2,510,508 |
About this award
The National Center for Advancing Translational Sciences issued a delivery order to Leidos Biomedical Research Inc. on September 15, 2025, with a ceiling value of $4.557 million to develop and qualify immunological assays and provide clinical sample testing for AAV-based gene therapy clinical candidates through September 14, 2030.
Place of performance is Frederick, Maryland. The order is priced on a cost-plus-fixed-fee basis and carries no set-aside. Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings Inc., operates the Frederick National Laboratory for Cancer Research as an FFRDC contractor serving NIH institutes. In fiscal year 2025, the order generated $64 thousand in invoiced federal service-contract labor, which Leidos performed in-house without subcontractor engagement.
Quick answers
Who was awarded contract 75N91025F00024?
75N91025F00024 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2025.
How much is contract 75N91025F00024 worth?
The government has obligated $4,557,516 on 75N91025F00024.
Which agency awarded contract 75N91025F00024?
National Cancer Institute (National Institutes of Health) awarded 75N91025F00024, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N91025F00024 an order under another contract?
Yes. 75N91025F00024 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91025F00024 competed?
The extent of competition for 75N91025F00024 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award